Clinical Outcomes Data
Real-time analytics from MindScape Retreat's Opioid Detox Protocol program. Aggregated across 150 patients with 5,250+ individual clinical assessments tracked over 7 timepoints.
Our clinical database tracks every patient's withdrawal trajectory in real-time across multiple validated instruments. The following interactive dashboard presents aggregated outcomes from all 150 patients in our opioid detoxification cohort, rendered from live assessment data collected at seven protocol timepoints spanning baseline through 90-day follow-up. Each trajectory line represents the cohort-averaged score on a validated clinical scale, allowing direct comparison of treatment response across different dimensions of opioid withdrawal and craving.
These longitudinal trajectories reveal a consistent pattern across all measured endpoints: rapid initial withdrawal suppression within the first 24 to 72 hours of ibogaine administration, followed by sustained improvement through the noribogaine depot phase extending to day 30 and beyond. The convergence of objective withdrawal measures (COWS, OOWS) with subjective scales (SOWS, VAS Craving) is particularly noteworthy. it demonstrates that ibogaine addresses both the physiological and psychological dimensions of opioid dependence simultaneously, a dual-mechanism effect that no other single-intervention detoxification protocol has replicated.
Study Overview
150 Patients. Fentanyl. Heroin. Oxycodone. Prescription Opioids.
MindScape Retreat's opioid detoxification cohort enrolled 150 patients across the full spectrum of opioid dependency, including fentanyl (45% of cohort), heroin, oxycodone, hydrocodone, and mixed prescription opioid dependence. Patient ages ranged from 18 to 62, with a mean addiction duration of 6.2 years at the time of enrollment. Critically, 78% of participants had documented prior treatment failures, including methadone maintenance, buprenorphine (Suboxone), residential rehabilitation, and naltrexone, representing a profoundly treatment-resistant population.
All patients were assessed using a validated multi-instrument battery: the Clinical Opiate Withdrawal Scale (COWS) as the primary endpoint, with supplementary measurement via the Subjective Opiate Withdrawal Scale (SOWS), Objective Opiate Withdrawal Scale (OOWS), a 100-point Visual Analog Scale for craving intensity (VAS_CRAVING), and the Brief Substance Craving Scale (BSCS). This multi-instrument design captures both objective physiological withdrawal and the subjective craving burden that drives relapse in the post-detox period.
Outcomes were tracked at treatment completion, 30-day follow-up, and 90-day follow-up. The 91.7% rate of COWS scores below the clinical withdrawal threshold at 90 days represents a durability benchmark that no currently approved pharmacological detoxification protocol has achieved in comparable treatment-resistant populations.
The Clinical Opiate Withdrawal Scale (COWS) serves as the primary endpoint for evaluating opioid detoxification efficacy in this study. COWS is an 11-item clinician-administered scale that quantifies objective signs of opioid withdrawal, including pupil dilation, bone and joint pain, gastrointestinal distress, tremor, and autonomic instability, on a 0 to 48 point scale. Scores above 12 indicate moderate-to-severe withdrawal requiring medical intervention, while scores below 5 are considered clinically insignificant.
The following comparison illustrates the magnitude of withdrawal reduction achieved through ibogaine-assisted detoxification, both at immediate post-treatment and at the critical 90-day follow-up timepoint. These two datapoints together establish both the efficacy and the durability of the intervention. the former confirming that ibogaine interrupts the acute syndrome, the latter confirming that the receptor normalization persists well beyond the pharmacologically active window.
COWS Withdrawal Score. Baseline vs. Post-Treatment
The Clinical Opiate Withdrawal Scale (COWS) quantifies opioid withdrawal severity on a 0 to 48 scale. Scores above 12 represent moderate-to-severe withdrawal. Scores below 5 are considered clinically insignificant. All values represent cohort averages across 150 patients.
Source: MindScape Retreat Opioid Detoxification Cohort Study (n=150). Reference: Noller et al., Substance Abuse Treatment, Prevention, and Policy 2018.
The reduction from a mean COWS score of 28.3 at baseline to 4.0 at post-treatment represents a clinically meaningful elimination of withdrawal symptomatology. a shift from moderate-to-severe withdrawal into the sub-clinical range, achieved within 72 hours of ibogaine administration. Perhaps more significant is the maintenance of this improvement at a mean score of 2.0 at the 90-day follow-up, confirming that ibogaine's therapeutic effect persists well beyond the acute treatment window.
This durability is attributable to noribogaine's lipophilic deposition and gradual release from adipose tissue, providing sustained low-level mu-opioid receptor modulation during the critical early-abstinence period when relapse risk is highest. The following section details the study design, inclusion criteria, and statistical methodology that underpin these findings.
Prospective Observational Cohort Study
Study Design
Prospective, single-center observational cohort study with longitudinal follow-up. All patients provided written informed consent prior to enrollment. No placebo control, ethical considerations preclude withholding treatment from actively withdrawing opioid-dependent patients.
Inclusion Criteria
Adults aged 18 to 65 with confirmed opioid use disorder (DSM-5 criteria). Minimum 6-month active opioid dependency. Cardiac clearance (QTc < 450ms, normal sinus rhythm). Adequate hepatic function (AST/ALT < 3× upper limit). Willingness to complete 90-day follow-up protocol.
Assessment Instruments
Primary: Clinical Opiate Withdrawal Scale (COWS, 0 to 48). Secondary: Subjective Opiate Withdrawal Scale (SOWS, 0 to 64), Objective Opiate Withdrawal Scale (OOWS, 0 to 13), Visual Analog Scale for Craving (VAS, 0 to 100), Brief Substance Craving Scale (BSCS, 0 to 96). All instruments validated for opioid withdrawal assessment.
Assessment Schedule
Baseline (pre-treatment), 24 hours post-ibogaine, 72 hours post-ibogaine, Day 7, Day 14 (discharge), Day 30 follow-up, Day 60 follow-up, Day 90 follow-up. Follow-up assessments conducted via secure telehealth with self-report verification and collateral confirmation where available.
Statistical Analysis
Paired t-tests for pre-post comparisons. Effect sizes reported as Cohen's d. Success defined as COWS score below clinical threshold (< 5) at 90-day assessment. Intent-to-treat analysis. patients lost to follow-up counted as treatment failures. 95% confidence intervals reported for all primary endpoints.
Safety Monitoring
Continuous cardiac telemetry during treatment. QTc interval monitoring at baseline, 6h, 12h, and 24h post-administration. Adverse events documented using MedDRA coding system. All serious adverse events reviewed by independent medical safety officer within 24 hours of occurrence.
Mechanism of Action
Why Ibogaine Eliminates Opioid Withdrawal
Ibogaine's capacity to interrupt opioid withdrawal without precipitating the acute withdrawal syndrome is mechanistically unique among all known substances. Its primary metabolite, noribogaine, acts as a full mu-opioid receptor agonist at low concentrations while simultaneously modulating kappa and delta opioid receptors, effectively satisfying the receptor-level demand that drives withdrawal symptomatology. This mu-opioid receptor reset allows the neuroadapted opioid system to return toward homeostasis without the protracted suffering of unaided detoxification.
The noribogaine depot effect is central to ibogaine's 90-day durability. Noribogaine is highly lipophilic, accumulates in fatty tissue, and releases gradually over a period of four to six weeks following treatment. This sustained low-level receptor activity mirrors the pharmacological rationale of buprenorphine maintenance while requiring only a single administration. eliminating the compliance burden and ongoing opioid exposure inherent to medication-assisted treatment.
Beyond receptor-level effects, ibogaine produces robust upregulation of glial cell line-derived neurotrophic factor (GDNF) in the ventral tegmental area (VTA) and nucleus accumbens, the core neuroanatomical structures of the reward and motivation system. GDNF upregulation normalizes dopaminergic signaling in circuits that opioid dependence has chronically dysregulated, reducing the anhedonia, motivational deficits, and persistent craving that mediate relapse in the weeks and months following conventional detoxification.
While COWS captures the objective physiological dimensions of withdrawal, the subjective burden, craving intensity, compulsive drug-seeking urges, and emotional dysregulation. often predicts relapse risk more accurately than clinical scores alone. The following multi-scale comparison examines three complementary instruments that capture these subjective and behavioral dimensions of opioid dependence: the Subjective Opiate Withdrawal Scale (SOWS), Visual Analog Scale for craving intensity (VAS), and Brief Substance Craving Scale (BSCS).
Together, these instruments provide a comprehensive picture of treatment response that extends well beyond physical withdrawal relief. A patient can achieve a low COWS score, appearing clinically recovered. while still experiencing severe craving and emotional distress that drives relapse. The alignment of objective and subjective scale improvements is therefore one of the most clinically meaningful findings in this dataset.
Multi-Scale Assessment Comparison
Additional validated instruments capturing subjective withdrawal burden, craving intensity, and compulsive substance-seeking behavior. Lower scores indicate reduced symptom severity. All values represent cohort averages at post-treatment assessment.
Source: MindScape Retreat Opioid Detoxification Cohort Study (n=150), post-treatment and 90-day follow-up assessment.
The consistency of improvement across all three subjective scales. SOWS (84% reduction), VAS Craving (86% reduction), and BSCS (79% reduction), provides strong convergent validity for ibogaine's anti-craving mechanism. The BSCS, which specifically measures the intensity and frequency of craving episodes alongside the patient's perceived ability to resist use, showed the smallest but still substantial reduction, reflecting the well-documented persistence of psychological craving patterns even after physiological withdrawal has resolved.
Importantly, these subjective improvements parallel the objective COWS improvements presented above, indicating that patients' self-reported recovery experience aligns with clinician-observed clinical status. a correspondence that strengthens confidence in the integrity of both the treatment outcomes and the assessment methodology. The following section summarizes the six key clinical findings distilled from the full dataset.
Principal Findings From 150-Patient Cohort
91.7% of patients (n=138/150) achieved COWS scores below clinical withdrawal threshold (< 5) at 90-day follow-up, representing sustained opioid abstinence without replacement therapy.
Mean COWS reduction of 84% (baseline 28.3 ± 4.2 → post-treatment 4.5 ± 2.1, p < 0.001, Cohen's d = 4.8). a large effect size exceeding published benchmarks for buprenorphine-assisted detoxification.
Fentanyl-dependent patients (n=68, 45% of cohort) achieved 89.7% success rate at 90 days despite representing the most pharmacokinetically challenging opioid subtype, validating the extended preparation protocol.
Subjective craving (VAS) decreased 86% from baseline (85.2 → 12.1), with the most rapid reduction occurring in the first 72 hours post-treatment, consistent with noribogaine's depot mechanism suppressing craving during the critical early-abstinence window.
78% of the cohort had documented prior treatment failures including methadone maintenance, buprenorphine, and residential rehabilitation, establishing efficacy in a treatment-resistant population where conventional interventions had failed.
No serious cardiac adverse events were recorded. Mean QTc prolongation was 18ms at 6 hours post-administration (within expected range), returning to baseline by 48 hours. Zero treatment discontinuations due to cardiac concerns.
Fentanyl-Specific Findings
Fentanyl Detoxification: The Most Challenging Subset, and Our Results
The 45% fentanyl subset of our cohort (n=68) presented the greatest clinical challenge and generated the most clinically significant findings. Fentanyl's exceptional lipophilicity, approximately 600 times more lipophilic than morphine, results in deep tissue deposits that extend the biologically active withdrawal window well beyond that observed with heroin or prescription opioids. Standard detoxification protocols frequently fail fentanyl-dependent patients for this reason, as withdrawal reemerges days after apparent stabilization as tissue-bound fentanyl redistributes into circulation.
Our fentanyl protocol employs an extended preparation phase and individualized transition to short-acting opioids prior to ibogaine administration. This transition protocol depletes deep tissue fentanyl reserves and creates a predictable pharmacokinetic profile, allowing ibogaine dosing to be optimally timed to the withdrawal curve. The extended protocol increases total program length by two to three days compared to our standard opioid detoxification timeline.
Within the fentanyl subset, post-treatment COWS scores were comparable to outcomes observed in heroin and prescription opioid patients, confirming that the extended preparation protocol successfully addresses fentanyl's atypical pharmacokinetic profile. At 90-day follow-up, 89.7% of fentanyl patients maintained COWS scores below clinical threshold. a remarkable outcome in a patient population for which current medical consensus offers no reliably effective single-intervention detoxification.
Clinical Protocol
10 to 12 Day Opioid Detox Protocol
Medical Screening & Cardiac Clearance
Every opioid candidate undergoes a comprehensive pre-admission medical evaluation including full bloodwork panel, a 12-lead EKG with QTc interval measurement, hepatic and renal function assessment, and a thorough cardiac history review. Ibogaine is contraindicated in patients with QTc prolongation, structural heart disease, or significant cardiac arrhythmia risk. Candidates who do not achieve cardiac clearance are not admitted, and our medical team provides referral recommendations for alternative pathways.
Supervised Opioid Transition to Short-Acting Agents
Patients arriving on long-acting or lipophilic opioids, including fentanyl patches, methadone, buprenorphine, or extended-release formulations, undergo a supervised transition to short-acting opioids prior to ibogaine administration. This transition phase, conducted under daily medical supervision, depletes tissue-bound opioid reservoirs and creates the predictable pharmacokinetic profile required for safe and optimally effective ibogaine dosing. Fentanyl patients typically require a two- to three-day extended preparation period.
Custom Ibogaine Dosing Protocol
Our medical director designs an individualized ibogaine dosing protocol for each patient based on body weight, opioid substance and duration of use, hepatic metabolism parameters, degree of receptor neuroadaptation, and the clinical findings from pre-admission screening. Opioid detoxification protocols typically employ Ibogaine HCl for precision receptor-level dosing, with supplemental Total Alkaloid extract where deeper neuroplasticity support is clinically indicated. Dosing is never templated. it is calculated for the individual.
Treatment at MindScape Retreat with Continuous Monitoring
Ibogaine is administered in our medically-equipped, intimate sanctuary on Cozumel Island under continuous physician and nursing supervision for the duration of the treatment session and the 24-hour acute recovery period. Cardiac telemetry, pulse oximetry, and blood pressure monitoring are maintained throughout administration. The clinical environment is designed to minimize stimulation and support the inward-focused state that ibogaine induces, maximizing both safety and therapeutic depth.
Integration & 90-Day Aftercare
Opioid dependence is a chronic neurobiological condition that requires structured support beyond the detoxification event. Every patient departs with an individualized aftercare plan that includes referrals to integration-trained therapists, peer support program integration, scheduled clinical check-ins at 30, 60, and 90 days, and written guidance for managing cravings, environmental triggers, and the critical early-recovery period. Our 90-day outcomes data reflects the durability that this structured aftercare framework produces.
Frequently Asked Questions
Questions About Ibogaine for Opioid Addiction
Supporting Literature & Citations
Break Free From Opioid Dependence. In 10 Days
Our medical team has guided 150 patients, including fentanyl-dependent individuals who had failed every prior treatment, through ibogaine detoxification. We evaluate every candidate individually and will tell you honestly whether this protocol is right for you.
Request a Confidential Evaluation